Marcy l’Etoile, le 23 septembre 2021
![20211001-Cynbiose-hawkcell-image-2](https://www.afssi.fr/wp-content/uploads/2021/10/20211001-Cynbiose-hawkcell-image-2-525x350.jpg)
Cynbiose SAS, a preclinical CRO, and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and large animals, join forces to offer a global R&D and commercial service for preclinical studies focused on the non-human primate model.
The partnership between Cynbiose and HawkCell will provide both a collaborative R&D offer with biopharmaceutical companies for the development and characterization of physiopathological models. It will also strengthen imaging capabilities for preclinical studies in the translational NHP model.